Ultragenyx Pharmaceutical INC Schedule 13G passive stakes

RTW Investments, LP and Roderick Wong, M.D. have filed a Schedule 13G, disclosing beneficial ownership of 7,796,895 shares of Ultragenyx Pharmaceutical Inc. common stock, representing 7.9% of the class.

AQR Capital Management, LLC and AQR Capital Management Holdings, LLC have filed a Schedule 13G, reporting beneficial ownership of 6,560,809 shares of Ultragenyx Pharmaceutical Inc. common stock, representing 6.66% of the class.

State Street Corporation has reported beneficial ownership of 6,158,766 shares, representing 6.3% of the outstanding common stock of Ultragenyx Pharmaceutical Inc., as of June 30, 2026.

Vanguard Portfolio Management has reported a beneficial ownership of 6.95% in Ultragenyx Pharmaceutical Inc. as of June 30, 2026.

Vanguard Capital Management has disclosed a beneficial ownership of 5.13% of Ultragenyx Pharmaceutical Inc.'s common stock as of June 30, 2026.

State Street Corporation has reported beneficial ownership of 5.1% of Ultragenyx Pharmaceutical Inc.'s common stock as of March 31, 2026.

Vanguard Portfolio Management has reported a beneficial ownership of 5.5% in Ultragenyx Pharmaceutical Inc., holding over 5.4 million shares.

The Vanguard Group reported zero beneficial ownership in Ultragenyx Pharmaceutical Inc. common stock following an internal corporate realignment.

FMR LLC and Abigail P. Johnson have filed an amendment to their Schedule 13G, disclosing a 3.5% beneficial ownership stake in Ultragenyx Pharma Inc. as of December 31, 2025.

FMR LLC and Abigail P. Johnson have disclosed beneficial ownership of 8.3% of Ultragenyx Pharma Inc.'s common stock as of September 30, 2025.

BlackRock, Inc. has filed an amended Schedule 13G, reporting a 5.1% beneficial ownership stake in Ultragenyx Pharmaceutical Inc. as of March 31, 2025.

Sands Capital Management, LLC and Frank M. Sands have filed an amended Schedule 13G, disclosing a 4.7% beneficial ownership stake in Ultragenyx Pharmaceutical Inc. as of December 31, 2024.

Wellington Management Group LLP and its affiliates have disclosed a beneficial ownership of 2.66% in Ultragenyx Pharmaceutical Inc. common stock as of December 31, 2024, held in the ordinary course of business.